Skip to main content
Midas Edge

INTELLIGENT BIO SOLUTIONS INC

For the period ended Mar 31, 2024. Filed May 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

INBS$1.97+11.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Shareholders’ Equity

For the three and nine months ended March 31, 2024 and 2023

Convertible preferred stock · Common stock · Treasury stock · Additional paid in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’
Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · income · interest · equity
Balance, June 30, 2023*-$-194,200$1,942(116)$(1)$46,180,112$(41,807,573)$(575,496)$(111,986)$3,686,998
Foreign currency translation loss--------(18,016)-(18,016)
Net loss-------(2,425,204)-(7,220)(2,432,424)
Balance, September 30, 2023 *--194,2001,942(116)(1)46,180,112(44,232,777)(593,512)(119,206)1,236,558
Issuance of common stock, Series E Preferred Stock and warrants, net of issuance costs5,728,72357,287186,0181,860--3,727,017---3,786,164
Conversion of convertible preferred shares into common stock(5,728,723)(57,287)477,3944,774--52,513----
Conversion of holdback Series C Preferred Stock into common stock--6,24862--32,700---32,762
Issuance of common stock upon cashless exercise Series F warrants--612,1826,122--(6,122)----
Foreign currency translation gain--------75,133-75,133
Net loss-------(1,969,641)-(6,742)(1,976,383)
Balance, December 31, 2023 *--1,476,04214,760(116)(1)49,986,220(46,202,418)(518,379)(125,948)3,154,234
Reverse stock split rounding adjustment--47,501475--(475)----
Issuance of common stock upon cash exercise of Series E warrants--629,4096,291--1,645,207---1,651,498
Issuance of restricted stock to vendors--42,760428--204,393---204,821
Issuance of common stock upon cashless exercise of Series F warrants--42,904429------429
Issuance of common stock, Series I, H1 and H2 warrants, net of issuance costs--675,1836,752--9,110,829---9,117,581
Foreign currency translation loss--------(144,026)-(144,026)
Net loss-------(2,977,667)-(9,098)(2,986,765)
Balance, March 31, 2024 *-$-2,913,799$29,135(116)$(1)$60,946,174$(49,180,085)$(662,405)$(135,046)$10,997,772
*Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.

Intelligent Bio Solutions Inc.

Condensed Consolidated Statements of Changes in Shareholders’ Equity*

For the three and nine months ended March 31, 2024 and 2023

Convertible preferred stock · Common stock · Treasury stock · Additional paid in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’
Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · income · interest · equity
Balance, June 30, 2022 *-$-62,042$620-$-$38,588,290$(31,175,853)$(788,135)$(79,151)$6,545,771
Foreign currency translation loss--------(135,559)-(135,559)
Net loss-------(1,208,293)-(5,785)(1,214,078)
Balance, September 30, 2022 *--62,042620--38,588,290(32,384,146)(923,694)(84,936)5,196,134
Issuance of Series C preferred stock and common stock for acquisition, net of issuance costs2,363,00323,63012,347124--4,700,517---4,724,271
Issuance of Series D preferred stock, net of issuance costs176,4621,765----160,695---162,460
Stock awards issued to employees--2,08421--259,979---260,000
Payment of tax withholding for employee stock awards----(116)(1)(14,407)---(14,407)
Foreign currency translation gain--------361,597-361,597
Net loss-------(420,600)-(6,471)(427,071)
Balance, December 31, 20222,539,46525,39576,473765(116)(1)43,695,074(32,804,746)(562,097)(91,407)10,262,984
Reverse stock split rounding adjustment--9389--(9)----
Issuance of common stock and warrants, net of issuance costs--54,583546--2,093,120---2,093,666
Issuance of common stock upon cashless exercise of warrants--8,46585--(85)----
Foreign currency translation loss--------(77,787)-(77,787)
Net loss-------(6,343,906)-(8,111)(6,352,017)
Balance, March 31, 20232,539,465$25,395140,459$1,405(116)$(1)$45,788,100$(39,148,652)$(639,884)$(99,518)$5,926,846

The accompanying notes are an integral part of these condensed consolidated financial statements.

*Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.